TARGET AUDIENCE
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of acute myeloid leukemia and myelodysplastic syndromes.

LEARNING OBJECTIVES

• Evaluate the importance of age, performance status and other biologic and disease-related factors in the selection and sequencing of therapy for patients with various presentations of acute myeloid leukemia (AML).
• Appreciate published clinical research findings with venetoclax in combination with azacitidine, decitabine or low-dose cytarabine for patients with newly diagnosed AML who are not eligible for intensive therapy, and identify individuals appropriate for treatment with this novel agent.
• Reflect on available research with approved and investigational FLT3 inhibitors, and use this information to guide clinical care and protocol opportunities for patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
• Develop an understanding of published data with and the current role of available IDH1/2 inhibitors for patients with newly diagnosed or relapsed/refractory AML and an IDH1 or IDH2 mutation, and incorporate these agents into current management algorithms.
• Assess the results from clinical trials examining the role of CPX-351 for patients with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes, and discern how this agent can be safely and optimally integrated into nonresearch care algorithms.
• Recall published research data with promising agents and investigational strategies under evaluation for AML, and counsel appropriately selected patients regarding clinical trial enrollment.
• Recognize the value of molecular testing for patients with myelodysplastic syndromes (MDS), and determine how various genetic alterations may affect MDS classification and risk assessment.
• Evaluate the importance of age, performance status, cytogenetic profile and other patient- and disease-related factors in the selection and sequencing of therapy for lower- and higher-risk MDS.
• Interrogate available research findings with oral hypomethylating agents for intermediate- and high-risk MDS to identify patients for whom this novel approach may be appropriate.
• Describe the biologic rationale for and available research findings with Bcl-2-targeted therapy for patients with high-risk MDS, and appraise the potential role of this strategy in current and future clinical care.
• Develop an understanding of the mechanisms of action of and available data with investigational therapies for higher-risk MDS to prepare for their potential availability in routine practice.
• Recollect the designs of ongoing clinical trials for patients with low- and high-risk MDS, and offer appropriate counseling about the potential benefits of participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
Presentations Program: This CME activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Uma Borate, MD, MS
Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University
The James Cancer Center
Columbus, Ohio

Consulting Agreements: AbbVie Inc, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Gilead Sciences Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Novartis, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc; Contracted Research: AbbVie Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Novartis; Data and Safety Monitoring Board/Committee: Takeda Pharmaceuticals USA.

Andrew H Wei, MBBS, PhD
Professor, Department of Haematology
Peter MacCallum Cancer Centre and Royal Melbourne Hospital
University of Melbourne
Walter and Eliza Hall Institute of Medical Research
Melbourne, Australia

Advisory Committee: AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Gilead Sciences Inc, Janssen Biotech Inc, MacroGenics Inc, Novartis, Pfizer Inc, Roche Laboratories Inc, Servier Pharmaceuticals LLC, Shoreline Biosciences; Consulting Agreements: Servier Pharmaceuticals LLC, Shoreline Biosciences; Research Funding to Institution: AbbVie Inc, Amgen Inc, Astex Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Janssen Biotech Inc, Novartis, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals Inc; Speakers Bureau: AbbVie Inc, Astellas, Bristol-Myers Squibb Company, Novartis, Servier Pharmaceuticals LLC; Nonrelevant Financial Relationship: Prof Wei is an employee of the Walter and Eliza Hall Institute (WEHI). WEHI receives milestone and royalty payments related to the development of venetoclax. Current and past employees of WEHI may be eligible for financial benefits related to these payments. Prof Wei receives such a financial benefit.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Jazz Pharmaceuticals Inc, and Taiho Oncology Inc.

Release date: April 2023
Expiration date: April 2024